

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

Bombay Stock Exchange Limited 1 st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u> Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan	National Stock Exchange of India Limited Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u> Kind Attn.: Famroze Pochara Asst. Vice President
Date: August 12, 2015	
Re.: <u>Unaudited financial results</u>	


Re.: Unaudited financial results for the quarter ended on June 30, 2015

We are forwarding herewith unaudited financial results for the quarter ended on June 30, 2015 reviewed by Audit Committee and taken on record by the Board of Directors on August 12, 2015 pursuant to Clause 41 of the Listing Agreement; the same may please receive in order.

Thanking you

Yours faithfully

For Cadila Healthcare Limited



Upen H. Shah
Company Secretary

Encl.: As above

Cadila Healthcare Limited

Registered Office: Zydlus Tower, Satellite Cross Roads, Ahmedabad - 380015

Tel. No.: (+91-79) 2686 8100 Fax No.: (+91-79) 2686 2365/66 Website: www.zyduscadila.com

CIN : 124230G11995PLC025878

Statement of Results for the Quarter Ended 30/06/2015

Particulars	Rupees in Lacs				
	COMPANY				
	3 Months ended 30/06/2015 (Unaudited)	Preceding 3 months ended 31/03/2015 (Audited)	Corresponding 3 months ended 30/06/2014 in the previous year (Unaudited)	Previous year ended 31/03/2015 (Audited)	
Income from operations					
Gross Sales	177,343	135,609	100,372	476,361	
Less: Excise Duty	2,053	1,853	1,681	7,752	
Net Sales	175,290	133,756	98,691	468,609	
Other operating income	16,212	11,639	12,588	59,834	
Total income from operations (net)	191,502	145,395	111,279	528,443	
Expenses					
Cost of materials consumed	35,985	29,678	31,655	128,606	
Purchases of stock-in-trade	10,900	12,666	11,537	44,150	
Changes in inventories of finished goods, work-in-progress and stock-in-trade	6,108	(536)	(5,189)	(7,598)	
Employee benefits expense	17,114	15,009	15,176	60,713	
Depreciation and amortisation expense	5,184	5,539	5,295	21,185	
Other expenses	49,512	42,282	31,715	149,161	
Total expenses	124,803	104,638	90,189	396,217	
Profit/ (Loss) from Operations before other income, finance costs and exceptional items (1-2)	66,699	40,757	21,090	132,226	
Other income	1,491	1,490	1,534	18,521	
Profit/ (Loss) from ordinary activities before finance costs and exceptional items (3+4)	68,190	42,247	22,724	150,747	
Finance costs	745	1,386	825	4,284	
Profit/ (Loss) from ordinary activities after finance costs but before exceptional items (5-6)	67,445	40,861	21,899	146,463	
Exceptional items	0	0	0	0	
Tax expense	67,445	40,861	21,899	146,463	
Net Profit/ (Loss) from ordinary activities after tax (9-10)	11,870	6,155	2,170	19,351	
Extraordinary items (net of tax expense)	55,575	34,706	19,729	127,112	
Net Profit/ (Loss) for the period (11-12)	0	0	0	0	
Pre-acquisition loss transferred to Goodwill arising on consolidation	0	0	0	0	
Minority interest	0	0	0	0	
Net Profit/ (Loss) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	55,575	34,706	19,729	127,112	
Paid-up equity share capital (Face Value Rs. 5/-)	10,237	10,237	10,237	10,237	
Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year				442,295	
Earnings per share (before extraordinary items)					
(of Rs. 5/- each) (not annualised):					
Basic (Rs.)	27.14	16.95	9.64	62.08	
Diluted (Rs.)	27.14	16.95	9.64	62.08	
Earnings per share (after extraordinary items)					
(of Rs. 5/- each) (not annualised):					
Basic (Rs.)	27.14	16.95	9.64	62.08	
Diluted (Rs.)	27.14	16.95	9.64	62.08	

Notes :

- [1] The above results for the quarter ended on June 30, 2015 were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on August 12, 2015.
- [2] The Statutory Auditors of the Company have carried out a "Limited Review" of the above results as per clause 41 of the Listing Agreement.
- [3] In consolidated results, other operating income for the quarter ended June 30, 2015 includes consideration of Rs. 6,666 Lacs (USD 10.5 Millions) received by Zydus Pharmaceuticals (USA) Inc., a wholly owned subsidiary company, on sale and transfer of ownership interest in certain Abbreviated New Drug Applications (ANDAs) for generic drug products.
- [4] Exceptional items in the consolidated results include:

No.	Particulars	Rupees in Lacs			
		3 Months ended 30/06/2015 (Unaudited)	Preceding 3 months ended 31/03/2015 (Audited)	3 months ended 30/06/2014 in the previous year (Unaudited)	Previous year ended 31/03/2015 (Audited)
a	Provision for various expenses related to the closure of business operations in Japan	0	(143)	118	(26)
b	Provision for amount payable to a former supplier for termination of supply contract, pursuant to the order passed by the Hon able High Court of Madrid, Spain	0	0	0	1,070
c	Payment made under Voluntary Retirement Scheme	211	0	0	0

[5] During the quarter, the Company has changed the initial invoking policy for supply of its products to its subsidiary companies. Consequently, there is a one-time impact on consolidated tax expense for the quarter ended June 30, 2015, which is higher by Rs. 6,154 Lacs, though it has no impact on consolidated gross sales and profit before tax.

[6] Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting period.

[7] The Company has one segment of activity viz. "Pharmaceuticals".

PART II

Select Information for the Quarter Ended 30/06/2015

3 Months ended 30/06/2015	Preceding 3 months ended 31/03/2015	3 months ended 30/06/2014 in the previous year	Previous year ended 31/03/2015		Particulars	3 Months ended 30/06/2015	Preceding 3 months ended 31/03/2015	3 months ended 30/06/2014 in the previous year	Previous year ended 31/03/2015
				A					
					PARTICULARS OF SHAREHOLDING				
				1	Public shareholding				
51,610,474	51,610,474	51,610,474	51,610,474		- Number of shares	51,610,474	51,610,474	51,610,474	51,610,474
25.21%	25.21%	25.21%	25.21%		- Percentage of Shareholding	25.21%	25.21%	25.21%	25.21%
				2	Promoters and Promoter Group Shareholding				
				a	Pledged / Encumbered				
					- Number of shares				
Nil	Nil	Nil	Nil		- Percentage of shares (as a % of the total shareholding of promoter and promoter group)				
N.A.	N.A.	N.A.	N.A.		- Percentage of shares (as a % of the total share capital of the company)				
N.A.	N.A.	N.A.	N.A.		Non - encumbered				
				b	- Number of shares				
153,138,046	153,138,046	153,138,046	153,138,046		- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	153,138,046	153,138,046	153,138,046	153,138,046
100.00%	100.00%	100.00%	100.00%		- Percentage of shares (as a % of the total share capital of the company)	100.00%	100.00%	100.00%	100.00%
74.79%	74.79%	74.79%	74.79%			74.79%	74.79%	74.79%	74.79%

3 months ended 30/06/2015	Particulars
NII	B
6	INVESTOR COMPLAINTS [In Numbers]
6	Pending at the beginning of the quarter
6	Received during the quarter
NII	Disposed of during the quarter
NII	Remaining unresolved at the end of the quarter

Ahmedabad, August 12, 2015

By Order of the Board,
For Cadila Healthcare Limited,

Pankaj R. Patel
Chairman & Managing Director